Lista de obras - Peter Horak - Dominio Público Uruguay

A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer

artículo científico publicado en 2007

Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

artículo científico publicado en 2021

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study

artículo científico publicado en 2014

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer

artículo científico publicado en 2005

Community-driven development of a modified progression-free survival ratio for precision oncology

scientific article published on 13 November 2019

Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia

artículo científico publicado en 2020

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer

artículo científico publicado en 2005

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

scientific article published on 09 April 2019

Finding Options Beyond Standard of Care in Oncology: A Proposal for Workflows Utilizing Knowledge Databases

artículo científico publicado en 2019

Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival

artículo científico publicado en 2005

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

artículo científico publicado en 2017

HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells

artículo científico publicado en 2014

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

artículo científico publicado en 2008

Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains

scientific article published on 26 September 2019

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.

artículo científico publicado en 2007

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls

artículo científico publicado en 2016

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

artículo científico publicado en 2019

Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.

artículo científico publicado en 2013

Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease

artículo científico publicado en 2020

Methylation status of TUSC3 is a prognostic factor in ovarian cancer

artículo científico publicado en 2012

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer.

artículo científico publicado en 2018

Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis

artículo científico publicado en 2010

Patient expectations are better for immunotherapy than traditional chemotherapy for cancer

artículo científico publicado en 2020

Personalized oncology

artículo científico publicado en 2017

Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.

artículo científico publicado en 2005

Precision oncology based on omics data: The NCT Heidelberg experience

artículo científico publicado en 2017

Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance

artículo científico publicado en 2007

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

artículo científico publicado en 2010

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

artículo científico publicado en 2004

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

artículo científico publicado en 2019

Sarcoma classification by DNA methylation profiling

artículo científico publicado en 2021

Successful BRAF/MEK inhibition in a patient with BRAF V600E-mutated extrapancreatic acinar cell carcinoma

artículo científico publicado en 2020

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast

artículo científico publicado en 2018

TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo

artículo científico publicado en 2014

TUSC3: functional duality of a cancer gene.

artículo científico publicado en 2017

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

artículo científico publicado en 2021

The landscape of chromothripsis across adult cancer types

artículo científico publicado en 2020

The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

artículo científico publicado en 2014

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.

artículo científico publicado en 2013

Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.

artículo científico publicado en 2015

Variant classification in precision oncology

artículo científico publicado en 2019

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer

artículo científico publicado en 2011

Lista de obras de Peter Horak

A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer

Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer

Community-driven development of a modified progression-free survival ratio for precision oncology

Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

Finding Options Beyond Standard of Care in Oncology: A Proposal for Workflows Utilizing Knowledge Databases

Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.

Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease

Methylation status of TUSC3 is a prognostic factor in ovarian cancer

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer.

Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis

Patient expectations are better for immunotherapy than traditional chemotherapy for cancer

Personalized oncology

Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.

Precision oncology based on omics data: The NCT Heidelberg experience

Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

Sarcoma classification by DNA methylation profiling

Successful BRAF/MEK inhibition in a patient with BRAF V600E-mutated extrapancreatic acinar cell carcinoma

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast

TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo

TUSC3: functional duality of a cancer gene.

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

The landscape of chromothripsis across adult cancer types

The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.

Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.

Variant classification in precision oncology

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer